1. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults;Min;AIDS,2011
2. I. Song, K. Adkison, M. Lovern, J. Chiu, J. Huang, C. Vavro, M. Ait-Khaled, B. Wynne, S. Min. Pharmacokinetic-pharmacodynamic modeling & simulation of the virologic response of dolutegravir in HIV-infected patients with integrase inhibitor resistant virus. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy 2015; Washington, DC. Abstract #14.
3. Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia;Katlama;J. Antimicrob. Chemother.,2016
4. I.H. Song, S. Chen, S. Piscitelli, S. Min Pharmacokinetics (PK) and PK-pharmacodynamic (PD) relationship of dolutegravir (DTG) in int grase inhibitor (INI)-naïve subjects, abstr A-1573. 53rd ICAAC, 10 to 13 September 2013, Denver, CO.
5. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients;Zhang;Br. J. Clin. Pharmacol.,2015